Anemia in patients with cancer can be caused by a number of factors including blood loss, hemolysis, nutritional deficiencies, renal insufficiency, marrow infiltration, anemia of chronic disease and ...

For those affected by anemia, receiving the proper treatment can improve quality of life. The most common treatment is erythropoiesis-stimulating agents (ESAs), which can provide significant ...

THE anemia of renal insufficiency is associated with both increased red-cell destruction and impaired erythropoietic response to anemia. Variations in the relative importance of these 2 mechanisms and ...

Two hundred-billion red blood cells are renewed in our body every single day. These erythrocytes (also known as red blood cells) are generated from bi-potent megakaryocyte-erythroid progenitor cells ...

Extramedullary hematopoiesis occurring in the myocardium has previously only been reported in a single case of a neonate with cyanotic congenital heart disease. Herein we report the incidental ...

Erythropoiesis-stimulating agents (ESAs) are a very effective treatment for reducing the need for transfusions in patients affected by anemia and either chronic kidney disease (CKD) or cancer. However ...

Erythropoiesis, the production of red blood cells from haematopoietic stem cells, is a finely balanced process that is essential for effective oxygen delivery throughout the body. This process ...

Radiation Oncology Services in the Modern Era: Evolving Patterns of Usage and Payments in the Office Setting for Medicare Patients From 2000 to 2010 The SEER-Medicare database was used to identify ...

Erythropoietin (EPO) is a hormone predominantly produced in the kidney, which is then released into blood. Erythropoietin promotes the production of red blood cells (erythropoiesis) in the bone marrow ...

THE administration of androgenic hormones to women with advanced breast cancer has been associated with an unusual alteration in erythropoietic activity. 1–10 This has consisted of increases in ...

Please provide your email address to receive an email when new articles are posted on . In 1989, epoetin alfa was approved by the FDA to treat anemia resulting from chronic kidney disease. Epoetin ...

Most anemic patients with non-deleted 5q lower-risk myelodysplastic syndromes (MDS) are treated with erythropoiesis-stimulating agents (ESAs), with a response rate of approximately 50%. Second-line ...